Overview:
The
global precision medicine market share is witnessing unprecedented growth due
to people turning their focus more on personal healthcare. It could attain an
astonishing CAGR of 12.5% during the forecast period (2023-2032). Medicine
evolved from the concept that same medicine cannot function equally for two
different individuals with the same disease as they have different gene
structure. At the same time, medication depends on how well patients can
respond to its dosage. Hence, the need for precision medicine. Market Research
Future (MRFR), in their report, has included various drivers and segments that
can produce a reliable prediction for the future market. Prevalent diseases
such as cancer, diabetes, and others are boosting the precision medicine
market report as treatment of such diseases gets a better result with
personalized medicine structure. Furthermore, its impact can significantly
lower the cost of treatment.
However,
a personal data breach can be seen as a major precision medicine market growth
prohibition. The diagnostic cost can incur a high cost, stringent government
policies, the risk with hardware and software failure, and lack of medical
framework can hold back the market during the forecast period.
Market Insights:
Mergers,
acquisitions, collaborations and other strategies dominate the market
substantially when it comes to strategic decisions. For instance, Roche
purchased Foundation Machine to better their portfolio. On the other hand, New
Medicine Partners is trying to increase their market reach by proposing a plan
based on personalized medicines to Kazakhstan officials to develop a plant
there.
Global
precision medicine market players include Abbott Laboratories (USA), Ab-Biotics
SA (USA), Almac Group Ltd. (UK), Asuragen Inc (USA), Biobase GmbH (Germany),
Biomérieux SA (France), Caris Life Sciences (USA), Cepheid Inc. (USA), Cetics
Healthcare Technologies Gmbh (Germany), GE Healthcare (USA), GlaxoSmithKline
PLC (UK), Healthcore Inc. (USA), IBM (USA), Innventis (Israel), Intel
Corporation (USA), Johnson & Johnson (USA), Laboratory Corporation Of
America Holdings (USA), Medtronic (USA), Molecular Health GmbH (Germany),
Novartis (Switzerland), Pfizer Inc. (USA), Qiagen (Germany), Quest Diagnostics
Inc (USA), Randox Laboratories Ltd. (UK), Sanofi Pharma (France), Takeda
Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd.
(Israel), and others.
Industry Trends:
Precision
medicine is showing great promise for the cure of the Alzheimer’s disease. Two
new drugs are waiting on the sideline for final approval; one called BAN2401
and the other Anavex 2-73. BAN2401’s use on patients shows a reduction in
generation of proteins called amyloid plaques that cause memory loss.
Recently,
an article published in SLAS Technology (Society for Laboratory Automation and
Screening) revealed that artificial intelligence (AI) is all set to impact
precision medicine industry significantly as it can efficiently analyze small
datasets and assist in the optimal design of drug combinations.
Segmentation:
The
global precision medicine market trends can be segmented by ecosystem,
sub-market, and therapeutics.
Based
on the ecosystem, the precision medicine market outlook can be segmented into
clinical laboratories, diagnostic tool companies, healthcare IT/ big data
companies, and pharma & biotech companies. Diagnostic tools segment has the
largest market volume.
Sub-market
segment of the precision medicine can be segmented by biomarker-based test,
companion diagnostics, molecular diagnostics, pharmacogenomics, targeted
therapeutics, and others. Company diagnostics is leading the segment.
Therapeutics-based
segmentation of the precision medicine
market overview includes cancer/oncology, cardiovascular disease, central
nervous system, infectious diseases, and others.
Regional Analysis:
Region-specific
analysis of the precision medicine market encompasses North America, Europe,
Asia Pacific (APAC), and the Middle East & Africa (MEA).
North
America is the largest market for global precision medicine. The region has
superior infrastructure, both in healthcare and biotechnology. It sets up the
zone perfectly for research and developments assisting further in new product
development.
Europe
is the second-largest market for global precision medicine. Various investors
are taking an interest in the sector and is helping in the development of new
drugs. However, the developing regions market particularly, the APAC will be
the fastest growing and is likely to be the key to the future. But the MEA
region may not find much thrust due to but can expect steady growth.
About US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street,5Th Floor, New York,
New
York 10013
United
States of America